Experimental models of endocrine responsive breast cancer: strengths, limitations, and use

Abstract

Breast cancers characterized by expression of estrogen receptor-alpha (ER; ESR1) represent approximately 70% of all new cases and comprise the largest molecular subtype of this disease. Despite this high prevalence, the number of adequate experimental models of ER+ breast cancer is relatively limited. Nonetheless, these models have proved very useful in advancing understanding of how cells respond to and resist endocrine therapies, and how the ER acts as a transcription factor to regulate cell fate signaling. We discuss the primary experimental models of ER+ breast cancer including 2D and 3D cultures of established cell lines, cell line- and patient-derived xenografts, and chemically induced rodent models, with a consideration of their respective general strengths and limitations. What can and cannot be learned easily from these models is also discussed, and some observations on how these models may be used more effectively are provided. Overall, despite their limitations, the panel of models currently available has enabled major advances in the field, and these models remain central to the ability to study mechanisms of therapy action and resistance and for hypothesis testing that would otherwise be intractable or unethical in human subjects.

Keywords

Breast cancer / experimental models / PDX / xenografts / study design

References

[1] Siegel RL,Fuchs HE.Cancer Statistics, 2021.CA Cancer J Clin2021;71:7-33

[2] Clarke R,Dixon JM.Endocrine resistance in breast cancer - an overview and update.Mol Cell Endocrinol2015;418:220-34 PMCID:PMC4684757

[3] Pan H,Braybrooke J.EBCTCG20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years.N Engl J Med2017;377:1836-46 PMCID:PMC5734609

[4] Kostev K.20-year risk of breast cancer recurrence.Breast Cancer Res Treat2018;168:765-6

[5] Beatson GT.On the treatment of inoperable cases of carcinoma of the mamma: suggestions from a new method of treatment, with illustrative cases.Trans Med Chir Soc Edinb1896;15:153-179 PMCID:PMC5518378

[6] Lonning PE.Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions.Ther Adv Med Oncol2012;4:127-37 PMCID:PMC3349075

[7] Barrios CH,Vinholes .What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer?.Ann Oncol2009;20:1157-62

[8] Cole MP,Todd IDH.A new antioestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46474.Br J Cancer1971;25:270-5

[9] Reinert T.Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review.Ther Adv Med Oncol2017;9:693-709 PMCID:PMC5764151

[10] Robertson JFR,Johnston S.Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies.NPJ Breast Cancer2021;7:11 PMCID:PMC7881093

[11] Robertson JFR,Trishkina E.Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.Lancet2016;388:2997-3005

[12] Robertson JFR,Noguchi S.Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer.Eur J Cancer2018;94:206-15

[13] Ellis MJ,Feltl D.Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study.J Clin Oncol2015;33:3781-7 PMCID:PMC4737861

[14] Robertson JFR,Lichfield J,Campbell C.Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.Eur J Cancer2021;145:19-28

[15] Josefsson ML.Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: meta-analyses of monotherapy, sequenced therapy and extended therapy.Breast2010;19:76-83

[16] Cristofanilli M,Bondarenko I.Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.Lancet Oncol2016;17:425-39

[17] Finn RS,Lang I.The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.Lancet Oncol2015;16:25-35

[18] Sledge GW Jr,Neven P.The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial.JAMA Oncol2019;29:116-24 PMCID:PMC6777264

[19] Im SA,Bardia A.Overall survival with ribociclib plus endocrine therapy in breast cancer.N Engl J Med2019;381:307-16

[20] Slamon DJ,Chia S.Overall survival with ribociclib plus fulvestrant in advanced breast cancer.N Engl J Med2019;382:514-24

[21] Huang M,Yan C,Zhang J.Small molecule HDAC inhibitors: Promising agents for breast cancer treatment.Bioorg Chem2019;91:103184

[22] Clarke R,Tan M.Systems biology: perspectives on multiscale modeling in research on endocrine-related cancers.Endoc Relat Cancer2019;26:R345-68 PMCID:PMC7045974

[23] Voskoglou-Nomikos T,Seymour L.Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models.Clin Cancer Res2003;9:4227-39

[24] Fang L,Zhang YW.Comparison of proteomics profiles between xenografts derived from cell lines and primary tumors of thyroid carcinoma.J Cancer2021;12:1978-89 PMCID:PMC7974514

[25] Holliday DL.Choosing the right cell line for breast cancer research.Breast Cancer Res2011;13:215 PMCID:PMC3236329

[26] Hatzis C,Juul BN.Enhancing reproducibility in cancer drug screening: how do we move forward?.Cancer Res2014;74:4016-23 PMCID:PMC4119520

[27] Lippman ME.Oestrogen-responsive human breast cancer in long term tissue culture.Nature1975;256:592-3

[28] Jordan VC.Prolonged antioestrogenic activity of ICI 46,474 in the ovariectomized mouse.J Reprod Fertil1975;42:251-8

[29] Jordan VC.50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened?.Endocr-Relat Cancer2021;28:R11-30 PMCID:PMC7780369

[30] Zardavas D,Swanton C.Clinical management of breast cancer heterogeneity.Nat Rev Clin Oncol2015;12:381-94

[31] Fan M,Clarke R,Li L.Radiogenomic signatures reveal multiscale intratumour heterogeneity associated with biological functions and survival in breast cancer.Nat Commun2020;11:4861 PMCID:PMC7519071

[32] Percie du Sert N,Alam S.Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0.PLoS Biol2020;18:e3000411 PMCID:PMC7360025

[33] Svendsen P,Dybkaer K.The application of human phase 0 microdosing trials: A systematic review and perspectives.Leuk Lymphoma2016;57:1281-90

[34] Arnedos M,Perez-Garcia J.Window of Opportunity trials for biomarker discovery in breast cancer.Curr Opin Oncol2019;31:486-492

[35] Wilson JL,Lin L.Scientific considerations for global drug development.Sci Transl Med2020;12:eaax2550 PMCID:PMC8158457

[36] Zhu Y,Liu MC.Estrogen receptor alpha (ER) positive breast tumors and breast cancer cell lines share similarities in their transcriptome data structures.Int J Oncol2006;29:1581-9

[37] Cope LM,Lopez-Bujanda Z.Do breast cancer cell lines provide a relevant model of the patient tumor methylome?.PLoS ONE2014;9:e105545 PMCID:PMC4144876

[38] Clarke R,Thompson EW.The inter-relationships between ovarian-independent growth, antiestrogen resistance and invasiveness in the malignant progression of human breast cancer.J Endocrinol1989;122:331-40

[39] Creighton CJ,Larios JM.Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors.Genome Biol2006;7:R28 PMCID:PMC1557996

[40] Kao J,Bocanegra M.Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.PLoS ONE2009;4:e6146 PMCID:PMC2702084

[41] Wen Y,Zhang S.Cell subpopulation deconvolution reveals breast cancer heterogeneity based on DNA methylation signature.Brief Bioinform2017;18:426-40

[42] Nass N.Tamoxifen resistance: from cell culture experiments towards novel biomarkers.Pathol Res Pract2015;211:189-97

[43] Neve RM,Fridlyand J.A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.Cancer Cell2006;10:515-27 PMCID:PMC2730521

[44] Vincent KM,Postovit LM.Assessing breast cancer cell lines as tumour models by comparison of mRNA expression profiles.Breast Cancer Res2015;17:114 PMCID:PMC4545915

[45] Jiang G,Yazdanparast A.Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer.BMC Genomics2016;17 Suppl 7:525 PMCID:PMC5001206

[46] Goodspeed A,Gray JW.Tumor-derived cell lines as molecular models of cancer pharmacogenomics.Mol Cancer Res2016;14:3-13 PMCID:PMC4828339

[47] Domcke S,Levine DA,Schultz N.Evaluating cell lines as tumour models by comparison of genomic profiles.Nat Commun2013;4:2126 PMCID:PMC3715866

[48] Kenny PA,Myers CA.The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression.Mol Oncol2007;1:84-96 PMCID:PMC2391005

[49] Wong C.The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance.J Steroid Biochem Mol Biol2012;131:83-92 PMCID:PMC3369003

[50] Chen S,Hong Y.New experimental models for aromatase inhibitor resistance.J Steroid Biochem Mol Biol2007;106:8-15 PMCID:PMC2743954

[51] Yue W,Chen S.A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene.Cancer Res1994;54:5092-5

[52] Hanahan D.The hallmarks of cancer.Cell2000;100:57-70

[53] Hanahan D.Hallmarks of cancer: the next generation.Cell2011;144:646-74

[54] Clarke R,Jones BC,Sengupta S.A systems biology approach to discovering pathway signaling dysregulation in metastasis.Cancer Metastasis Rev2020;39:903-18 PMCID:PMC7487029

[55] Stuelten CH,Montell DJ.Cell motility in cancer invasion and metastasis: insights from simple model organisms.Nat Rev Cancer2018;18:296-312 PMCID:PMC6790333

[56] Aitman TJ,Churchill GA,Mackay TF.The future of model organisms in human disease research.Nat Rev Genet2011;12:575-82

[57] Olarerin-George AO.Assessing the prevalence of mycoplasma contamination in cell culture via a survey of NCBI's RNA-seq archive.Nucleic Acids Res2015;43:2535-42 PMCID:PMC4357728

[58] Iyama K,Lo SC.Effects of mycoplasmal LAMPs on receptor responses to steroid hormones in mammalian cells.Curr Microbiol2001;43:163-9

[59] Laborda-Illanes A,Dominguez-Recio ME.Breast and gut microbiota action mechanisms in breast cancer pathogenesis and treatment.Cancers (Basel)2020;12:4016-23 PMCID:PMC7565530

[60] Chen J,Prasath V.The microbiome and breast cancer: a review.Breast Cancer Res Treat2019;178:493-6

[61] Somaschini A,Nuzzo A.Cell line identity finding by fingerprinting, an optimized resource for short tandem repeat profile authentication.Genet Test Mol Biomarkers2013;17:254-9

[62] Nims RW.Best practices for authenticating cell lines.In Vitro Cell Dev Biol Anim2017;53:880-7

[63] Barretina J,Stransky N.The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.Nature2012;483:603-7 PMCID:PMC3320027

[64] Lorsch JR,Lippincott-Schwartz J.Cell Biology. Fixing problems with cell lines.Science2014;346:1452-3 PMCID:PMC5101941

[65] Buschhaus JM,Eckley SS.Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow.Oncogene2020;39:5649-62 PMCID:PMC7442734

[66] Franco-Barraza J,Amatangelo MD.Preparation of extracellular matrices produced by cultured and primary fibroblasts.Curr Protoc Cell Biol2016;71:10 PMCID:PMC5058441

[67] Justus CR,Ruiz-Echevarria M.In vitro cell migration and invasion assays.J Vis Exp2014;51046 PMCID:PMC4186330

[68] Hafner M,Chung M.Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs.Nat Methods2016;13:521-7 PMCID:PMC4887336

[69] Eastman A.Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays.Oncotarget2017;8:8854-66 PMCID:PMC5352448

[70] Haverty PM,Tan J.Reproducible pharmacogenomic profiling of cancer cell line panels.Nature2016;533:333-7

[71] Kennedy DG,Clarke R.The effect of the rate of cell proliferation on the synthesis of methotrexate poly-γ-glutamates in two human breast cancer cell lines.Biochem Pharmacol1985;34:3087-90

[72] Kreso A,van GP.Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer.Science2013;339:543-8

[73] Kooistra T,Toet K,van den Hoogen RM.Stimulation of tissue-type plasminogen activator synthesis by retinoids in cultured human endothelial cells and rat tissues in vivo.Thromb Haemost1991;65:565-72

[74] Soule HD,Long A,Brennan M.A human cell line from a pleural effusion derived from a human breast carcinoma.J Natl Cancer Inst1973;51:1409-16

[75] Agthoven T, van Agthoven TL, Portengen H, Foekens JA, Dorssers LC. Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells.Cancer Res1992;52:5082-8

[76] Clarke R,Katzenellenbogen BS.Progression from hormone dependent to hormone independent growth in MCF-7 human breast cancer cells.Proc Natl Acad Sci U S A1989;86:3649-53 PMCID:PMC287195

[77] Brünner N,Fojo A,Lippman ME.Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications.Cancer Res1993;53:283-90

[78] Brünner N,Jirus S.MCF7/LCC9: An antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182, 780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.Cancer Res1997;57:3486-93

[79] Butler WB.Varied responses to retinoic acid of tamoxifen-sensitive and tamoxifen-resistant sublines of the human breast cancer cell line MCF-7.Proc Am Assoc Cancer Res1989;30305

[80] Lykkesfeldt AE,Briand P.Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,790 sensitive human breast cancer cell line, MCF-7/TAMR-1.Cancer Res1994;54:1587-95

[81] Jensen BL,Lykkesfeldt AE.Differential regulation of specific genes in MCF-7 and the ICI 182,780-resistant cell line MCF-7182R-6.Br J Cancer1999;79:386-92 PMCID:PMC2362436

[82] Naundorf H,Lykkesfeldt AE.Development and characterization of a tamoxifen-resistant breast carcinoma xenograft.Br J Cancer2000;82:1844-50 PMCID:PMC2363223

[83] Masamura S,Heitjan DF.Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells.J Clin Endocrinol Metab1995;80:2918-25

[84] Lewis JS,Meeke K.Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal.J Steroid Biochem Mol Biol2005;94:131-41

[85] Lewis JS,Osipo C.Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation.J Natl Cancer Inst2005;97:1746-59

[86] Keydar I,Karby S.Establishment and characterization of a cell line of human carcinoma origin.Eur J Cancer1979;15:659-70

[87] Murphy CS,Jordan VC.Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions.Cancer Res1990;50:7285-92

[88] Pink JJ,Assikis J.Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation.Br J Cancer1996;74:1227-36 PMCID:PMC2075946

[89] Park WC,Macgregor SJ.Deregulation of estrogen induced telomerase activity in tamoxifen-resistant breast cancer cells.Int J Oncol2005;27:1459-66

[90] Graham ML,Miller LA.T47DCO cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance.Cancer Res1990;50:6208-17

[91] Ribas R,Guest SK.AKT antagonist AZD5363 influences estrogen receptor function in endocrine-resistant breast cancer and synergizes with fulvestrant (ICI182780) in vivo.Mol Cancer Ther2015;14:2035-48

[92] Engel LW,Tralka TS,O'Brien SJ.Establishment and characterization of three new continuous cell lines derived from human breast carcinomas.Cancer Res1978;38:3352-64

[93] den Berg HW, Lynch M, Martin J, Nelson J, Dickson GR, Crockard AD. Characterization of a tamoxifen-resistant variant of the ZR-75-1 human breast cancer cell line (ZR-75-9a1) and stability of the resistant phenotype.Br J Cancer1989;59:522-6

[94] den Berg HW, Martin J, Lynch M. High progesterone receptor concentration in a variant of the ZR-75-1 human breast cancer cell line adapted to growth in oestrogen free conditions.Br J Cancer1990;61:504-7

[95] Long B,Lynch M.Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line.Br J Cancer1992;65:865-9 PMCID:PMC1977788

[96] Kangaspeska S,Jaiswal A.Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer.BMC Cancer2016:16:378 PMCID:PMC4932681

[97] Clarke R.Animal models of breast cancer: their diversity and role in biomedical research.Breast Cancer Res Treat1996;39:1-6

[98] Clarke R.Animal models of breast cancer:experimental design and their use in nutrition and psychosocial research. Breast.Cancer Res Treat1997;46:117-33

[99] Clarke R.Human breast cancer cell line xenografts as models of breast cancer. The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines.Breast Cancer Res Treat1996;39:69-86

[100] Clarke R.Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models.Breast Cancer Res Treat1997;46:255-78

[101] Shultz LD,Ishikawa F,Lyons BL.Human cancer growth and therapy in immunodeficient mouse models.Cold Spring Harb Protoc2014;2014:694-708 PMCID:PMC4411952

[102] Percie du SN,Ahluwalia A.The ARRIVE guidelines 2.0: updated guidelines for reporting animal research.Exp Physiol2020;105:1459-66 PMCID:PMC7610926

[103] Yamamoto S,Kanamori T,Namba M.In vitro studies on potentiation of cytotoxic effects of anticancer drugs by interferon on a human neoplastic cell line (HeLa).Cancer Lett1983;20:131-8

[104] Mantell N.Evaluation of survival data and two new rank order statistics arising in its consideration.Cancer Chemother Rep1966;50:163-70

[105] Hanfelt J.Statistical approaches to experimental design and data analysis of in vivo studies.Breast Cancer Res Treat1997;46:279-302

[106] Rygaard K."GROWTH"- a computer program for determination of mean growth curves and calculation of response to therapy of solid tumor xenografts. In: Wu B, Zheng J, editors. Immune-deficient animals in experimental medicine. Basel: Karger; 1989. p. 301-6.

[107] Pantelouris EM.Absence of thymus in a mutant mouse.Nature1968;217:370-1

[108] Bulun SE,Imir G.Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment.Pharmacol Rev2005;57:359-83

[109] Zhao H,Brooks DC.A novel promoter controls Cyp19a1 gene expression in mouse adipose tissue.Reprod Biol Endocrinol2009;7:37 PMCID:PMC2684739

[110] Golovine K,Vanselow J.Three different promoters control expression of the aromatase cytochrome p450 gene (cyp19) in mouse gonads and brain.Biol Reprod2003;68:978-84

[111] Sflomos G,Metsalu T.A preclinical model for ERalpha-positive breast cancer points to the epithelial microenvironment as determinant of luminal phenotype and hormone response.Cancer Cell2016;29:407-22

[112] Steeg PS.Targeting metastasis.Nat Rev Cancer2016;16:201-18 PMCID:PMC7055530

[113] Murayama T.Patient-derived xenograft models of breast cancer and their application.Cells2019;8:621 PMCID:PMC6628218

[114] Holen I,Morrissey B.In vivo models in breast cancer research: progress, challenges and future directions.Dis Model Mech2017;10:359-71 PMCID:PMC5399571

[115] Matthews SB.Steroid hormone receptor positive breast cancer patient-derived xenografts.Horm Cancer2017;8:4-15 PMCID:PMC5291783

[116] du MS,Bras-Goncalves R.Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse.Mol Oncol2014;8:431-43 PMCID:PMC5528550

[117] Eirew P,Khattra J.Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution.Nature2015;518:422-6 PMCID:PMC4864027

[118] Skibinski A.The origin of breast tumor heterogeneity.Oncogene2015;34:5309-16 PMCID:PMC4734640

[119] Dobrolecki LE,Alferez DG.Patient-derived xenograft (PDX) models in basic and translational breast cancer research.Cancer Metastasis Rev2016;35:547-73 PMCID:PMC5396460

[120] Finlay-Schultz J,Riley D.New generation breast cancer cell lines developed from patient-derived xenografts.Breast Cancer Res2020;22:68 PMCID:PMC7310532

[121] Drobysheva D,McDowell M,Ekiz HA.Transformation of enriched mammary cell populations with polyomavirus middle T antigen influences tumor subtype and metastatic potential.Breast Cancer Res2015;17:132 PMCID:PMC4589945

[122] Maglione JE,Young LJ.Transgenic polyoma middle-T mice model premalignant mammary disease.Cancer Res2001;61:8298-305

[123] Diaz-Cruz ES,Gallicano GI,Furth PA.Comparison of increased aromatase versus ERalpha in the generation of mammary hyperplasia and cancer.Cancer Res2011;71:5477-87 PMCID:PMC3405850

[124] Bonner MR,Nie J.Breast cancer risk and exposure in early life to polycyclic aromatic hydrocarbons using total suspended particulates as a proxy measure.Cancer Epidemiol Biomarkers Prev2005;14:53-60

[125] Steck SE,Eng SM.Cooked meat and risk of breast cancer--lifetime versus recent dietary intake.Epidemiology2007;18:373-82

[126] Nie J,Bonner MR.Exposure to traffic emissions throughout life and risk of breast cancer: the Western New York Exposures and Breast Cancer (WEB) study.Cancer Causes Control2007;18:947-55

[127] Mordukhovich I,Herring AH.Polymorphisms in DNA repair genes, traffic-related polycyclic aromatic hydrocarbon exposure and breast cancer incidence.Int J Cancer2016;139:310-21 PMCID:PMC5295853

[128] Huggins C,Brillantes FP.Mammary cancer induced by a single feeding of polynuclear hyrocarbons, and its suppression.Nature1961;189:204

[129] Jordan VC.Tamoxifen: catalyst for the change to targeted therapy.Eur J Cancer2008;44:30-8 PMCID:PMC2566958

[130] Zhang X,Zhang H.Maternal obesity increases offspring's mammary cancer recurrence and impairs tumor immune response.Endocr Relat Cancer2020;27:469-82 PMCID:PMC7424355

[131] Russo J,Rogers AE,Wellings SR.Comparative study of human and rat mammary tumorigenesis.Lab Invest1990;62:244-78

[132] Herschkowitz JI,Weigman VJ.Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.Genome Biol2007;8:R76 PMCID:PMC1929138

[133] Samuelson E,Walentinsson A,Behboudi A.Absence of Ras mutations in rat DMBA-induced mammary tumors.Mol Carcinog2009;48:150-5

[134] Abba MC,Lee J.DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutations.Oncotarget2016;7:64289-99 PMCID:PMC5325442

[135] Hilakivi-Clarke LA,Bouker KB.Effects of in utero exposure to ethinyl estradiol on tamoxifen resistance and breast cancer recurerence in a preclinical model.J Natl Cancer Inst2017;109:1-11 PMCID:PMC6255695

[136] Cook KL,Clarke PAG.Endoplasmic reticulum stress protein GRP78 modulates lipid metabolism to control drug sensitivity and antitumor immunity in breast cancer.Cancer Res2016;76:5657-70 PMCID:PMC5117832

[137] de Assis S,Cruz MI.High-fat or ethinyl-oestradiol intake during pregnancy increases mammary cancer risk in several generations of offspring.Nat Commun2012;3:1053 PMCID:PMC3570979

[138] Zhang X,Warri A.Lifetime genistein intake increases the response of mammary tumors to Tamoxifen in rats.Clin Cancer Res2017;23:814-24 PMCID:PMC5654585

[139] Yin Y,Russell RG.Characterization of medroxyprogesterone and DMBA-induced multilineage mammary tumors by gene expression profiling.Mol Carcinog2005;44:42-50

[140] Mohibi S,Band H.Mouse models of estrogen receptor-positive breast cancer.J Carcinog2011;10:35 PMCID:PMC3263010

[141] de Oliveira KD,Tedari MV.Chemical carcinogenesis by DMBA (7,12-dimethylbenzanthracene) in female BALB/c mice: new facts.Brazil J Vet Res Animal Sci2015;52:125-33

[142] Buqué A,Perez-Lanzón M.Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.Nat Commun2020;11:3819 PMCID:PMC7393498

[143] Le NA,Vasson MP.EO771, is it a well-characterized cell line for mouse mammary cancer model?.Cancer Med2020;9:8074-85 PMCID:PMC7643677

[144] Le NA,Diab M.EO771, the first luminal B mammary cancer cell line from C57BL/6 mice.Cancer Cell Int2020;20:328 PMCID:PMC7372867

[145] Johnstone CN,Cao Y.Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer.Dis Model Mech2015;8:237-51 PMCID:PMC4348562

[146] Dekkers JF,Sachs N.Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids.Nat Protoc2021;16:1936-65 PMCID:PMC8221035

[147] Houthuijzen JM.Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment.Cancer Metastasis Rev2018;37:577-97

[148] Buchsbaum RJ.Breast cancer-associated fibroblasts: where we are and where we need to go.Cancers (Basel)2016;8:19 PMCID:PMC4773742